

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/519,352	08/19/2005	Jan Matthias Braun	5008.01US01	3048
62274 DARDL& ASS	7590 11/28/200 SOCIATES, PLLC	EXAMINER		
220 S. 6TH ST. SUITE 2000, U.S. BANK PLAZA MINNEAPOLIS, MN 55402			TONGUE, LAKIA J	
			ART UNIT	PAPER NUMBER
	10,1111100102		1645	
			MAIL DATE	DELIVERY MODE
			11/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)	
10/519,352	BRAUN ET AL.	
Examiner	Art Unit	
LAKIA J. TONGUE	1645	

The amendment document filed on <u>15 August 2008</u> is considered non-compliant because it has failed to meet the requirements of 37 CFR 1 121 or 1.4. In order for the amendment document to be compliant, expending of the fail-

item(s) is required.	ment document to be compliant, correction of the following
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AME  1. Amendments to the specification:  A. Amended paragraph(s) do not include mart  B. New paragraph(s) should not be underlined  C. Other	kings.
2. Abstract:     A. Not presented on a separate sheet. 37 CFF     B. Other	R 1.72.
"Annotated Sheet" as required by 37 CFR  B. The practice of submitting proposed drawin	the top margin as "Replacement Sheet," "New Sheet," or 1.121(d). g correction has been eliminated. Replacement drawings s, in compliance with 37 CFR 1.84 are required.
<ul> <li>C. Each claim has not been provided with the of each claim cannot be identified. Note: t number by using one of the following status (Previously presented), (New), (Not entered</li> </ul>	present.  xt of all pending claims (including withdrawn claims) proper status identifier, and as such, the individual status he status of every claim must be indicated after its claim is identifiers: (Original), (Currently amended), (Canceled), d), (Withdrawn) and (Withdrawn-currently amended), not been presented in ascending numerical order.
5. Other (e.g., the amendment is unsigned or not signed	ned in accordance with 37 CFR 1.4):
For further explanation of the amendment format required by	37 CFR 1.121, see MPEP § 714.
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:	
<ol> <li>Applicant is given no new time period if the non-complia filed after allowance. If applicant wishes to resubmit the entire corrected amendment must be resubmitted.</li> </ol>	ant amendment is an after-final amendment or an amendmen non-compliant after-final amendment with corrections, the
(including a submission for a request for continued exam amendment filed within a suspension period under 37 CF	following: a preliminary amendment, a non-final amendment ination (RCE) under 37 CFR 1.114), a supplemental 'R 1.103(a) or (c), and an amendment filed in response to a , the correction required is only the corrected section of the
Extensions of time are available under 37 CFR 1.136 amendment or an amendment filed in response to a Q	6(a) <u>only</u> if the non-compliant amendment is a non-final uayle action.
filed in response to a Quayle action; or	int amendment is a non-final amendment or an amendment amendment is a preliminary amendment or supplemental
/Robert A. Zeman/ for Lakia J. Tongue, Examiner of Art Unit 1645	

<sup>--</sup> The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Continuation Sheet (PTOL-324)

Application No. 10/519,352

Continuation of 4(e) Other: Applicants were to amend claim 12 to be commensurate in scope with independent claim 1 so it could be examined together with the other elected claims, however, claim 12 as amended is not commensurate in scope. Claim 12 requires LOS from commensal bacteria with cross-reactive antigens to Moraxella catarrhalis, while claim 1 requires LOS from commensal Moraxella catarrhalis with cross-reactive antigens to Neisseria meningitidis. Consequently, claim 12 is withdrawn from consideration as it is drawn to a non-elected invention.